Literature DB >> 9393564

The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.

P Rougier1, J P Neoptolemos.   

Abstract

Over the last 10 years important advances have been made in the treatment of patients with advanced colorectal cancer, particularly with surgery either alone or in combination with radiotherapy. Furthermore, despite early scepticism, several chemotherapy studies have now reported significant clinical benefits with 5-FU-based regimens and promising results have also been reported with newer agents such as raltitrexed and irinotecan. Taken together these advances now enable a significant proportion of patients to undergo treatment which will improve their quality of life, prolong survival and even result in cure in certain cases. Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393564     DOI: 10.1016/s0748-7983(97)93715-x

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer.

Authors:  Lara Bellardita; Simona Donegani; Andrea L Spatuzzi; Riccardo Valdagni
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

2.  Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy.

Authors:  Chang-Zheng Du; Jie Li; Yong Cai; Ying-Shi Sun; Wei-Cheng Xue; Jin Gu
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

3.  Improved Overall Survival of Colorectal Cancer under Multidisciplinary Team: A Meta-Analysis.

Authors:  Dong Peng; Yu-Xi Cheng; Yong Cheng
Journal:  Biomed Res Int       Date:  2021-05-01       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.